 |
|
March 27, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
 |
- Beyond Air: Resignation of Steve
Lisi, CEO, and Appointment of Robert
Goodman, Chief Commercial Officer, as CEO
More
- Eisai: To Begin Enrolling Phase 2 Study in
Patients With Narcolepsy
More
- Glucotrack: To File Significant IDE With FDA
for US Clinical Trial in Early Q2 Based on
Critical 2025 Milestones More
- Hoth Therapeutics: Deploys OpenClaw AI
Platform to Accelerate Drug Discovery More
- Intelligent Bio Solutions: Strengthens
European IP Portfolio With Eighth Patent Grant
More
- Kamada: FDA Approval of its Plasma
Collection Center in San Antonio, Texas More
- Made Scientific and New Jersey Institute of
Technology: Partnership to Enhance
Graduate-Level Cell and Gene Therapy
Bioprocessing Curriculum More
- Neion Bio: Emerges From Stealth With
Multi-Product Biosimilar Partnership
Leveraging Its Cutting-Edge Genetic
Engineering Platform
More
More
More
- Novo Nordisk: FDA Approves Awiqli, the First
and Only Once-Weekly Basal Insulin Treatment
for Adults With Type 2 Diabetes More
More*
- Nuvation Bio and Eisai: Marketing
Authorisation Application for Taletrectinib
for the Treatment of Advanced ROS1-Positive
Non-Small Cell Lung Cancer Validated by the
European Medicines Agency More
- NYU Langone Health: Updated Cholesterol
Guideline Shifts Focus to Lifelong Prevention
More
- Organon: Debuts New Analysis of VTAMA
(tapinarof) Cream, 1%, Phase 3 Pooled Data
Demonstrating Early and Consistent Skin
Clearance and Itch Improvement in Atopic
Dermatitis Patients Down to 2 Years of Age More
- Rocket Pharmaceuticals: FDA Approval
of KRESLADI for Pediatric Patients With
Severe Leukocyte Adhesion Deficiency-I
(LAD-I) More
More*
- Tevogen: Advances Strategic CRO Evaluation
to Expand Clinical Research Delivery
Capabilities and Drive Revenue Growth More
- The Rockefeller University: Key Driver of
Long-Term Inflammatory Memory Identified More
|
|
-
- ADMA Biologics: Issues Statement Refuting
Unsubstantiated, Misleading and Inaccurate
Allegations by Culper Research More
- LB Pharmaceuticals: Fourth Quarter and Full
Year 2025 Financial Results and Corporate
Update
More
- SIGA: Declares Special Cash Dividend of
$0.60 Per Share More
- The Michael J. Fox Foundation for
Parkinson's Research: New Report: In 2024,
Parkinson’s Disease Cost the U.S. $82.2
Billion, Surpassing Previous Projections More
|
|
- Anavex Not Giving Up on Alzheimer’s Drug
After EU Rejection More*
- More on Antibodies Connecting Cancer With
Autoimmune Brain Disease More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- 11 Companies Hiring Clinical Professionals
Now More
- 11 Companies Hiring Now in New York More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- Hiring Outlook: February Brings First YOY
Job Increase Since 2022 More
- ICYMI: CEO's Perspective: Big Moves Come
with Big Responsibilities More
- ICYMI: CEO's Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- Recursion Appoints Former Exelixis CMO; More
Executive Moves at Incyte More*
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: NYC Life Science Company
Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:NYC,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
